Has Timothy Yap, MD received payments from drug or device companies?

Yes. Drug and device makers reported $56,735,590 in general payments to Timothy Yap, MD across 2,710 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Timothy Yap, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Timothy Yap, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Timothy Yap, MD

Medical Oncology · Houston, TXNPI 1942743216

Payments from drug & device makers

$56,735,590in general payments, 2019–2025

Across 2,710 payments — averaging $20,936 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$23.2M
AstraZeneca$5M
GSK$4.7M
Bayer$4.3M
Merck$4.3M
Astrazeneca UK Limited$1.4M
plus $13.8M from 38 others

$26,940in research payments, 2019–2025

Across 28 payments — averaging $962.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$22K
Eli Lilly$4K
Regeneron$675

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	692	$23,201,219
AstraZeneca	14	$4,989,097
GSK	92	$4,743,061
Bayer	379	$4,312,658
Merck	140	$4,312,031
Astrazeneca UK Limited	15	$1,420,048
Roche Products Limited	302	$1,395,425
Eli Lilly	21	$1,190,298
EMD Serono Research & Development Institute, Inc.	4	$1,182,519
Tesaro, Inc.	18	$1,146,560
Beigene, Ltd.	121	$1,056,856
EMD Serono, Inc.	209	$975,212
Ipsen Bioscience Inc.	9	$897,009
Beigene USA, Inc.	16	$781,632
Blueprint Medicines Corporation	42	$634,863
Exelixis Inc.	275	$630,227
Biontech SE	66	$590,731
Clovis Oncology, Inc.	10	$545,059
E.r. Squibb & Sons, L.L.C.	24	$543,910
Beone Medicines USA, Inc.	9	$472,801
Novartis	12	$308,287
Sanofi US Services Inc.	12	$287,730
Genentech, Inc.	31	$263,781
Regeneron	24	$238,580
Springworks Therapeutics, Inc.	45	$207,773
Sumitomo Pharma America, Inc.	85	$177,385
Kyowa Kirin Pharmaceutical Development, Inc	4	$103,413
Seagen Inc.	3	$49,569
F. Hoffmann-la Roche AG	4	$18,683
Merck Kgaa	3	$12,486
Hoffmann-la Roche Limited	2	$10,270
Siemens Medical Solutions USA, Inc.	4	$8,318
Amgen	1	$7,788
Otsuka Pharmaceutical Co., Ltd.	3	$4,012
Jazz Pharmaceuticals Inc.	3	$3,296
Daiichi Sankyo Inc.	1	$2,911
AbbVie	2	$2,822
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$1,900
Institut DE Recherches Internationales Servier	2	$1,700
Kyowa Kirin, Inc.	2	$1,470
Varian Medical Systems, Inc.	2	$1,300
Tersera Therapeutics LLC	1	$681
Merck Healthcare Kgaa	4	$200
Boehringer Ingelheim	1	$20

How this compares

$56,735,590 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas →

Medicare billing

Part B allowed, 2024

$37,688

Medicare patients

110

Services billed

265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Houston

Hagop KantarjianHouston$100.5M
Yasir ElaminHouston$41.3M
David HongHouston$31.6M
Guillermo Garcia-ManeroHouston$31.6M
Jason WestinHouston$30.8M
Lucia MasarovaHouston$29.7M
Jordi Rodon AhnertHouston$28.1M
Sarina Piha PaulHouston$26M
Jenny ChangHouston$17.8M
Hun LeeHouston$15.3M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →